drugset / Trial / NCT02211937

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

NCT02211937

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative oral bioavailability of 400 mg BI 44847 as suspension vs. 400 mg BI 44847 as tablet, to investigate a food effect on the 400 mg tablet pharmacokinetic (PK) and to investigate relative oral bioavailability of 40 mg BI 44847 as solution vs. 40 mg BI 44847 as tablet.

Timeline

Start
2007-01
Primary completion
2007-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator BI 44847 Unknown 40 mg Oral
Comparator BI 44847 Unknown 400 mg Oral

Indications

No indication recorded.